10x Genomics, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
None of our directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2026, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:
On March 13, 2026, Shehnaaz Suliman, amember of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 28,616 shares of the Company’s common stock as well additional shares of the Company’s common stock anticipated to be received from potential restricted stock units expected to vest between August 2026 and May 2027, subject to certain conditions. The expiration date of the trading arrangement is June 30, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.